PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28331226-0	2017	The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL.	givinostat	34-44	cytokine receptor like factor 2	Homo sapiens	99-104	
28331226-4	2017	Here, we found that givinostat inhibited proliferation and induced apoptosis of BCP-ALL CRLF2-rearranged cell lines, positive for exon 16 JAK2 mutations.	givinostat	20-30	cytokine receptor like factor 2	Homo sapiens	88-93	
28331226-10	2017	Lastly, the selective killing of cancer cells by givinostat may allow the design of reduced intensity regimens in CRLF2-rearranged Down syndrome-associated BCP-ALL patients with an overall benefit in terms of both toxicity and related complications.	givinostat	49-59	cytokine receptor like factor 2	Homo sapiens	114-119